Alcoholic hepatitis

被引:11
作者
Agarwal K. [1 ]
Kontorinis N. [1 ]
Dieterich D.T. [1 ]
机构
[1] Department of Medicine, Mount Sinai Medical Center, New York, NY 10029-6574, One Gustave Levy Place
关键词
Infliximab; Orthotopic Liver Transplantation; Pentoxifylline; Alcoholic Hepatitis; Acamprosate;
D O I
10.1007/s11938-004-0004-6
中图分类号
学科分类号
摘要
Alcoholic hepatitis (AH) is a common disease associated with significant morbidity and mortality. Most often the diagnosis is suggested by a history of heavy alcohol excess in a patient with features of hepatic decompensation. In its purest form, AH is a histologic diagnosis of acute hepatic inflammation in response to alcohol. The primary objective of treatment for AH is to support long-term alcohol abstinence and to achieve adequate nutrition with lifestyle modification; goal setting and education are integral to long-term medical management. Severity at presentation (calculated by way of the Maddrey score) determines outcome. Patients with AH represent a heterogeneous group with regard to severity and pathogenesis, with various therapeutic interventions assessed in patients with severe AH. To date, corticosteroids have been studied most, and despite remaining controversial, warrant a place in the treatment of selected patients. Recent advances in unraveling the aspects of disease pathogenesis in AH have raised the possibility of targeted therapies, such as anti-tumor necrosis factor-α monoclonals and pentoxifylline. Orthotopic liver transplantation is not recommended for patients with severe acute AH, as most have an unclear long-term prognosis in the context of ongoing excess alcohol ingestion at presentation. Copyright © 2004 by Current Science Inc.
引用
收藏
页码:451 / 458
页数:7
相关论文
共 26 条
[1]  
Haber P.S., Warner R., Seth D., Et al., Pathogenesis and management of alcoholic hepatitis, J. Gastroenterol. Hepatol., 18, pp. 1322-1344, (2003)
[2]  
Maddrey W.C., Boitnott J.K., Bedine M.S., Et al., Corticosteroid therapy for alcoholic hepatitis, Gastroenterology, 75, pp. 193-199, (1978)
[3]  
Said A., Williams J., Holden J., Et al., Model for end stage liver disease predicts mortality across a broad spectrum of liver disease, J. Hepatol., 40, pp. 897-903, (2004)
[4]  
Garbutt J.C., West S.L., Carey T.S., Et al., Pharmacological treatment of alcoholic dependence: A review of the evidence, JAMA, 281, pp. 1318-1325, (1999)
[5]  
Mezey E., Potter J.J., Rennie-Tankersley L., Et al., A randomized trial placebo trial of vitamin E for alcoholic hepatitis, J. Hepatol., 40, pp. 40-46, (2004)
[6]  
McClain C.J., Hill D.B., Song Z., Et al., S-Adenosylmethionine, cytokines and alcoholic liver disease, Alcohol, 27, pp. 185-192, (2002)
[7]  
Lieber C.S., New concepts of the pathogenesis of alcoholic liver disease, Curr. Gastroenterol. Rep., 6, pp. 60-65, (2004)
[8]  
Mathurin P., Duchatelle V., Ramond M.J., Et al., Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone, Gastroenterology, 110, pp. 1847-1853, (1996)
[9]  
Carithers R.L., Herlong F., Diehl A.M., Et al., Methylprednisolone therapy in patients with severe alcoholic hepatitis, Ann. Intern. Med., 110, pp. 685-690, (1989)
[10]  
Mathurin P., Mendenhall C., Carithers Jr. R.L., Et al., Corticosteroids improve short term survival in patients with sever alcoholic hepatitis (AH): Individual data analysis of the last three randomized placebo controlled trials, J. Hepatol., 36, pp. 480-487, (2002)